by Kristen Markus | Aug 13, 2021 | Clinical trial, Evidence generation, Health outcomes, Market access, Medical affairs
Clinical evidence generation: clinical trials Health researchers continually discover new evidence that deepens our understanding of disease processes and progression. This rapidly evolving knowledge must be integrated into ongoing research and development of new...
by Kristen Markus | Aug 13, 2021 | Evidence synthesis, Health outcomes, Healthcare, Market access
What is evidence synthesis? As the pharmaceutical market rapidly evolves to keep pace with patient needs and emerging research, healthcare decision makers must continuously re-evaluate the evidence base that informs their thinking. But how can they take into account...
by Anna Pagotto | Jul 6, 2021 | Market access, NICE, Oncology
The rapid development of immuno-oncology (I-O) therapies has transformed the cancer treatment landscape, but health technology assessment (HTA) agencies can decide against covering or reimbursing such treatments because of their complexity and high cost. As experts in...
